Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
31 January 2014Website:
http://www.ultragenyx.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:42:30 GMTDividend
Analysts recommendations
Institutional Ownership
RARE Latest News
Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p
Ultragenyx (RARE) announces disappointing first-quarter 2024 results, falling short of earnings and revenue expectations, despite growth in Crysvita and Dojolvi sales compared to the previous year.
Although the financial results for Ultragenyx (RARE) in the quarter ending March 2024 provide an overview of the company's performance, it may be beneficial to analyze how certain key metrics measure up against Wall Street forecasts and previous year's figures.
Ultragenyx (RARE) reported a quarterly loss of $2.03 per share, which was higher than the Zacks Consensus Estimate of a loss of $1.72 per share. This is an improvement from the loss of $2.33 per share reported in the same quarter last year.
Ultragenyx (RARE) announces encouraging interim results from the phase I/II trial of GTX-102 for Angelman syndrome, but the stock decreases because of safety worries.
A conference call has been scheduled for Monday, April 15 at 8:00 a.m. ET. Please use the updated registration link provided below. The call will take place in Novato, California.
Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.
Ultragenyx Pharmaceutical, Inc. (RARE) Q4 2023 Earnings Call Transcript
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 1(current)
- 2
What type of business is Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company headquartered in Novato, California, specializing in the development and implementation of new drugs for the treatment of severe rare genetic diseases. It was founded in 2010. The company focuses its efforts on developing drugs for patients with diseases that have no treatment options. Today, there are many rare genetic diseases that do not have approved therapies. The company's product portfolio includes two commercially approved products, as well as several candidates at various stages of clinical trials, which can be divided into three categories: biologics, gene therapy products, and small molecules.
What sector is Ultragenyx Pharmaceutical in?
Ultragenyx Pharmaceutical is in the Healthcare sector
What industry is Ultragenyx Pharmaceutical in?
Ultragenyx Pharmaceutical is in the Biotechnology industry
What country is Ultragenyx Pharmaceutical from?
Ultragenyx Pharmaceutical is headquartered in United States
When did Ultragenyx Pharmaceutical go public?
Ultragenyx Pharmaceutical initial public offering (IPO) was on 31 January 2014
What is Ultragenyx Pharmaceutical website?
https://www.ultragenyx.com
Is Ultragenyx Pharmaceutical in the S&P 500?
No, Ultragenyx Pharmaceutical is not included in the S&P 500 index
Is Ultragenyx Pharmaceutical in the NASDAQ 100?
No, Ultragenyx Pharmaceutical is not included in the NASDAQ 100 index
Is Ultragenyx Pharmaceutical in the Dow Jones?
No, Ultragenyx Pharmaceutical is not included in the Dow Jones index
When does Ultragenyx Pharmaceutical report earnings?
The next expected earnings date for Ultragenyx Pharmaceutical is 02 August 2024